Selective noradrenaline reuptake inhibitors for schizophrenia-Reference-Cited by-同舟云学术

Selective noradrenaline reuptake inhibitors for schizophrenia

Published:2018-01-25 Issue:1 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Matthews Paul R L¹,Horder Jamie²,Pearce Michael³

Affiliation:

1. Kildare West Wicklow MHS; North Kildare Mental Health Service; Celbridge Community Health Centre Shackleton Road Celbridge Co. Kildare Ireland

2. King's College London; Department of Forensic and Neurodevelopmental Sciences; Institute of Psychiatry De Crespigny Park London UK SE5 8AF

3. Oxford Health NHS Foundation Trust; Department of General and Older Adult Psychiatry; Warneford Hospital, Warneford Lane, Oxford UK OX3 7JX

Publisher

Wiley

Subject

Pharmacology (medical)

Reference133 articles.

1. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine;Ball;Clinical Schizophrenia & Related Psychoses,2011

2. NCT00176436 Double-blind study of atomoxetine for weight management in patients taking olanzapine or clozapine www.clinicaltrials.gov (first received 2005)

3. NCT00089869 A combination of two currently approved drugs to enhance the treatment of schizophrenia www.clinicaltrials.gov (first received 2004)

4. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia;Friedman;Journal of Clinical Psychopharmacology,2008

5. NCT00488163 Pilot study of atomoxetine to enhance cognition in patients with schizophrenia www.clinicaltrials.gov (first received 2007)

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of high-quality nursing on neurological function psychological moods quality of life of elderly patients with stroke;Frontiers in Neurology;2023-10-16

2. Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy;Pharmaceutics;2023-02-17

3. Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder;Advances in Clinical and Experimental Medicine;2022-11-30

4. Influence of Evidence-Based Nursing on Psychological Status, Neurological Function, and Life Quality of Patients with Acute Poststroke Depression;Disease Markers;2022-09-16

5. Mirtazapine in schizophrenia – an undeservedly overlooked option?;International Clinical Psychopharmacology;2022-03-31